D&D PharmaTech Co.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's … Read more
D&D PharmaTech Co. (347850) - Total Assets
Latest total assets as of March 2025: ₩88.53 Billion KRW
Based on the latest financial reports, D&D PharmaTech Co. (347850) holds total assets worth ₩88.53 Billion KRW as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
D&D PharmaTech Co. - Total Assets Trend (2022–2024)
This chart illustrates how D&D PharmaTech Co.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
D&D PharmaTech Co. - Asset Composition Analysis
Current Asset Composition (December 2024)
D&D PharmaTech Co.'s total assets of ₩88.53 Billion consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩30.01 Billion | 0.0% |
| Accounts Receivable | ₩3.04 Billion | 3.1% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩7.73 Billion | 7.9% |
| Intangible Assets | ₩32.48 Billion | 33.3% |
| Goodwill | ₩2.09 Billion | 2.2% |
Asset Composition Trend (2022–2024)
This chart illustrates how D&D PharmaTech Co.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: D&D PharmaTech Co.'s current assets represent 40.8% of total assets in 2024, an increase from 35.6% in 2022.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, the same as 0.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, a decrease from 46.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 33.3% of total assets.
D&D PharmaTech Co. Competitors by Total Assets
Key competitors of D&D PharmaTech Co. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
D&D PharmaTech Co. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - D&D PharmaTech Co. generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - D&D PharmaTech Co. is currently not profitable relative to its asset base.
D&D PharmaTech Co. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.54 | 4.11 | 4.11 |
| Quick Ratio | 3.54 | 4.11 | 4.11 |
| Cash Ratio | 2.80 | 3.50 | 3.50 |
| Working Capital | ₩23.73 Billion | ₩ 33.51 Billion | ₩ 33.51 Billion |
D&D PharmaTech Co. - Advanced Valuation Insights
This section examines the relationship between D&D PharmaTech Co.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 48.13 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 23.1% |
| Total Assets | ₩97.50 Billion |
| Market Capitalization | $484.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values D&D PharmaTech Co.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: D&D PharmaTech Co.'s assets grew by 23.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for D&D PharmaTech Co. (2022–2024)
The table below shows the annual total assets of D&D PharmaTech Co. from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩97.50 Billion | +23.10% |
| 2023-12-31 | ₩79.20 Billion | -15.42% |
| 2022-12-31 | ₩93.64 Billion | -- |